In order to promote human health and care for diseases, Joe Biomedical has taken "compassionate compassion" as the foundation of his business. He is actively investing in research and development of natural plant new drugs.
The company's new JBM-TC4 plant medicine (patent-protected) was successfully developed using its core technology and valued natural Chinese herbal medicines. In March 2013, the company officially obtained FDA-Phase II human clinical approval, and in May it successfully passed the TFDA approval. Phase clinical trials. It is expected that the successful development of JBM-TC4 plant new drugs will provide more effective treatment options for cancer patients in the world, and the compound ingredients of plant drugs can be used together with single-component small molecule drugs, which is the trend of integrated cancer treatment in the future. By helping each other to expand the anti-cancer effect, it can also reduce the unpleasant side effects of single-component small molecule drugs. It can reduce the side effects of treatment for cancer patients and greatly improve the quality of life.
In order to make full use of the existing core technologies and original materials, the R&D team is gradually realizing the R&D-oriented Botanical New Drug Project and actively launching the implementation schedule of the Biotech New Drug Program. In July 2013, the company also applied for approval to pass the “Biotechnology” of the Ministry of Economic Affairs. New Drug R&D Company's qualification certification.
With his compassion and compassion, Qiao Bensheng’s doctors have established the roots of Qiaoben's business, scientifically and rigorously screened safe and non-toxic Taiwanese native materials, combined with abundant research and development energy of industry officials, actively developed new plant drugs and promoted them to the international pharmaceutical market, praying for the health of all human beings. Medical quality contributes.